Literature DB >> 28986513

Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.

Elif Hindié1, Clément Morgat, Paolo Zanotti-Fregonara, Magalie Haissaguerre, Laurence Bordenave, Antoine Tabarin.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28986513     DOI： 10.2967/jnumed.117.202630

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  2 in total

Review 1.  Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.

Authors:  Shagufta Shaheen; Farshad Moradi; Gerardo Gamino; Pamela L Kunz
Journal:  Curr Treat Options Oncol       Date:  2020-03-14

2.  Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.

Authors:  Wei-Lin Lo; Shih-Wei Lo; Su-Jung Chen; Ming-Wei Chen; Yuan-Ruei Huang; Liang-Cheng Chen; Chih-Hsien Chang; Ming-Hsin Li
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.